Malignancies and cyclophosphamide exposure in Wegener's granulomatosis.
Bernatsky
Sasha
S
Ramsey-Goldman
Rosalind
R
Clarke
Ann E
AE
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy*; D006801:Humans; D009153:Mutagens / Q000009:adverse effects*; D009369:Neoplasms / Q000139:chemically induced*; D018570:Risk Assessment
D018501:Antirheumatic Agents; D009153:Mutagens; D003520:Cyclophosphamide